Aura Biosciences, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

CARGO Therapeutics Inc. executed the 21st initial public offering in the US by a biopharmaceutical company in 2023 and the fifth-largest so far this year when it grossed $281.3m from an offering of 1

The pace of IPOs in 2022 is far below the record-breaking number of first-time offerings in 2021, with the last initial public offering in the US by a biopharmaceutical company completed by Acrivon T

Intracellular medicines pioneer Entrada Therapeutics, Inc. , cancer drug developer Aura Biosciences, Inc. and dermatology-focused Biofrontera Inc. launched initial public offerings on 28 October,